The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“The EGFR has an important role in the regulation of growth and diVerentiation of a large number of diVerent cell types (for review, see [55]).”
BackgroundSmith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241 · cited 1×
“Dromedary, Camel and Llama) as a second class of antibodies next to the conventional (four-chain) antibody repertoire [21].”
BackgroundPhage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., & Parks, W. P. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1417 · Cited by 2,289
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Cited by
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
“Therefore, VHHs have been targeted to normally long-lived serum proteins such as albumin (Coppieters et al. 2006; Roovers et al. 2007) or immunoglobulin (Harmsen et al. 2005a) using bispecific VHHs recognizing these serum proteins in addition to the therapeutic target, resulting in half-lives that…”
BackgroundInfluentialA general protocol for the generation of Nanobodies for structural biology
Pardon, E., Laeremans, T., Triest, S., Rasmussen, S. G. F., Wohlkönig, A., Ruf, A., Muyldermans, S., Hol, W. G. J., Kobilka, B. K., & Steyaert, J. (2014) · Nature Protocols · doi:10.1038/nprot.2014.039 · Cited by 790
Self-citationThe therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Strategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 513
Albumin as a versatile platform for drug half-life extension
Sleep, D., Cameron, J., & Evans, L. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.023 · Cited by 485
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
Albumin and its application in drug delivery
Sleep, D. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.993313 · Cited by 464
New frontiers in nanotechnology for cancer treatment
Alexis, F., Rhee, J.-W., Richie, J. P., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.017 · Cited by 347
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
“and can be fused to other antibody fragments to create bsAbs with favorable kinetics [31].”
BackgroundIron oxide nanoparticles for targeted cancer imaging and diagnostics
Rosen, J. E., Chan, L., Shieh, D.-B., & Gu, F. X. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.08.017 · Cited by 329
Nanobodies and Their Potential Applications
Hassanzadeh-Ghassabeh, G., Devoogdt, N., De Pauw, P., Vincke, C., & Muyldermans, S. (2013) · Nanomedicine · doi:10.2217/nnm.13.86 · Cited by 328
Role of ErbB Receptors in Cancer Cell Migration and Invasion
Appert-Collin, A., Hubert, P., Crémel, G., & Bennasroune, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00283 · Cited by 310
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Self-citationNanobodies: Next Generation of Cancer Diagnostics and Therapeutics
Yang, E. Y., & Shah, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01182 · Cited by 291
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & van Bergen en Henegouwen, P. M. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26145 · Cited by 284
Self-citationDisplay technologies: Application for the discovery of drug and gene delivery agents☆
SERGEEVA, A., KOLONIN, M., MOLLDREM, J., PASQUALINI, R., & ARAP, W. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.018 · Cited by 266
Nanobody-Based Cancer Therapy of Solid Tumors
Kijanka, M., Dorresteijn, B., Oliveira, S., & van Bergen en Henegouwen, P. M. (2015) · Nanomedicine · doi:10.2217/nnm.14.178 · Cited by 265
Self-citationFormatted single-domain antibodies can protect mice against infection with influenza virus (H5N2)
Tillib, S. V., Ivanova, T. I., Vasilev, L. A., Rutovskaya, M. V., Saakyan, S. A., Gribova, I. Y., Tutykhina, I. L., Sedova, E. S., Lysenko, A. A., Shmarov, M. M., et al. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2012.12.014 · Cited by 54
(2023) · doi:10.3390/vaccines11050919 · Cited by 50
Metadata
- Authors
- Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., de Haard, H. J., & van Bergen en Henegouwen, P. M. P.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2006-05-30
- Volume
- 56
- Issue
- 3
- Pages
- 303-317
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2030205190
- Cited by
- 346
- References
- 51
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.